Creative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsThe advent of Chimeric Antigen Receptor T-cell (CAR-T) therapies has revolutionized the field of oncology, providing new avenues for treating various forms of cancer. Our 20 years of experience in the biotechnology sector have equipped us with the expertise and technological capabilities to support the entire lifecycle of CAR-T products, from early development to commercialization.
EXPLORE MORETo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsGet a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MOREAll products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Creative Biolabs leverages the advantages of biocompatible materials to deliver a comprehensive portfolio of biocompatible materials-based artificial T cell stimulator products. These products are designed to address the developmental limitations inherent in T cell therapies and, consequently, to accelerate the progress of immunotherapy research.
The success of T cell therapies relies on the precise management of T cell activation and growth. Conventional methods often face limitations in achieving the desired specificity, potency, and safety. As highlighted in recent research, the need for advanced tools is evident. Biocompatible materials offer a promising avenue for creating artificial T cell stimulators that can mimic natural antigen-presenting cells (APCs) with greater precision and control. This method overcomes the drawbacks of conventional techniques, resulting in T cell therapies that are both more effective and safer.
Fig.1 Classification of acellular artificial T cell stimulators.1
Creative Biolabs offers a comprehensive suite of biocompatible materials-based artificial T cell stimulator products designed to streamline your T cell therapy research and development. Our focus is on the engineering of biocompatible materials designed to conjugate signals that stimulate T cells, with the objective of achieving precise control over T cell activation. By precisely conjugating ligands, such as antibodies against CD3, CD28, and other co-stimulatory molecules, to biocompatible materials, our artificial T cell stimulators that closely mimic the natural T cell activation process are created. This approach offers significant advantages, enabling researchers to fine-tune T cell responses with unprecedented precision. The controlled activation of T cells, achieved through our products, translates to enhanced experimental reproducibility, improved cell therapy efficacy, and a deeper understanding of T cell biology.
Q1: Are all T cell subtypes compatible with your biocompatible materials-based artificial T cell stimulators?
A1: Our products are designed to target specific T cell subtypes. Moreover, we can customize specific products to meet your unique requirement. This customization process involves modifying the surface ligands of the biocompatible materials to selectively engage with the desired T cell subtypes. Furthermore, we can adjust the stimulation conditions, including the concentration of ligands and the duration of stimulation, to optimize the activation and expansion of your target T cell population.
Q2: Can these stimulators be used for both in vitro and in vivo studies?
A2: Our stimulators are primarily designed for in vitro applications. We also offer solutions that can be adapted for in vivo use. This adaptation process may involve further modifications to the biocompatible materials, such as optimizing their size, surface charge, and degradation profile, to ensure biocompatibility, minimize off-target effects, and enhance their delivery to the target site.
Furthermore, we have developed a platform for engineering cells that conjugate T cell-stimulating signals, thereby enhancing T cell activation efficiently. Additionally, we offer tailored development services for artificial T cell stimulators using commonly utilized biocompatible materials:
Creative Biolabs is a top supplier of cutting-edge solutions for the study and advancement of cell therapy. Our biocompatible materials-based artificial T cell stimulator products are supported by years of experience in immunology, cell treatment, and biomaterial engineering. We are constantly improving our technologies and services to achieve the desired results and high-quality products for each customer. Please feel free to get in touch with us for detailed information.
Reference
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
